Can Melike Hazal, Sweeney Sedona, Allwood Brian W, Dorman Susan E, Cohen Ted, Menzies Nicolas A
Department of Global Health and Population, Harvard T H Chan School of Public Health, Harvard, Boston, MA, USA.
Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.
Lancet Glob Health. 2025 Jul;13(7):e1240-e1249. doi: 10.1016/S2214-109X(25)00114-7.
Untreated pulmonary tuberculosis causes ongoing lung damage, which can persist after treatment. Conventional modelling approaches for assessing tuberculosis health effects might not fully capture these mechanisms. We evaluated how tuberculosis-associated lung damage and post-tuberculosis sequelae affect the lifetime health consequences of tuberculosis in high HIV prevalence settings.
We developed a microsimulation model (computer simulations that reproduce disease natural history and intervention effects for sampled individuals) representing dynamic changes in lung function for individuals evaluated for tuberculosis in routine clinical settings. We parametrised the model with data (from a previously published study) for three African countries with a high burden of tuberculosis and HIV: Uganda, Kenya, and South Africa, and estimated lifetime health outcomes under prompt, delayed, and no tuberculosis treatment scenarios. We compared results to earlier modelling approaches that omit progressive lung damage and post-tuberculosis sequelae.
We estimated a 5·1 years (95% uncertainty interval 3·8-6·4) reduction in life expectancy due to tuberculosis with prompt treatment, 7·7 years (5·5-10·1) with delayed treatment, and 18·5 years (15·5-20·6) with no treatment. Estimated per-person disability-adjusted life-years (DALYs) from tuberculosis were 11·4 years (8·9-14·2) with prompt treatment, 17·1 years (13·1-22·1) with delayed treatment, and 37·7 years (34·3-40·3) with no treatment. Compared with individuals without HIV, individuals with HIV had a greater proportion of tuberculosis-attributable deaths, but fewer life-years lost to tuberculosis. Post-tuberculosis DALYs represented 52·5% of total DALYs with prompt treatment, 42·7% with delayed treatment, and 9·1% with no treatment. Modelling approaches that omit progressive lung damage and post-tuberculosis sequelae underestimated lifetime health losses of tuberculosis by 48-57% and underestimated the benefits of prompt treatment by 45-64%.
Delayed initiation of tuberculosis treatment causes greater lung damage and higher mortality risks during and after the disease episode than prompt treatment. In settings with coprevalent tuberculosis and HIV, accounting for these factors substantially increased estimates of the lifetime disease burden and life expectancy loss caused by tuberculosis. These findings imply greater health effects and cost-effectiveness for interventions to prevent tuberculosis and achieve earlier treatment initiation than indicated in previous analytical approaches.
US National Institutes of Health.
未经治疗的肺结核会持续损害肺部,这种损害在治疗后可能依然存在。评估结核病对健康影响的传统建模方法可能无法完全捕捉这些机制。我们评估了在艾滋病毒高流行地区,与结核病相关的肺部损害和结核病后遗症如何影响结核病对终生健康的后果。
我们开发了一个微观模拟模型(通过计算机模拟为抽样个体重现疾病自然史和干预效果),以反映在常规临床环境中接受结核病评估的个体肺功能的动态变化。我们使用来自三个结核病和艾滋病毒负担较重的非洲国家(乌干达、肯尼亚和南非)的数据(来自先前发表的一项研究)对该模型进行参数设置,并估计在及时治疗、延迟治疗和不进行结核病治疗的情况下的终生健康结果。我们将结果与早期忽略进行性肺损伤和结核病后遗症的建模方法进行了比较。
我们估计,及时治疗的情况下,结核病导致预期寿命减少5.1年(95%不确定区间3.8 - 6.4年),延迟治疗为7.7年(5.5 - 10.1年),不治疗为18.5年(15.5 - 20.6年)。结核病导致的人均伤残调整生命年(DALY)在及时治疗时为11.4年(8.9 - 14.2年),延迟治疗时为17.1年(13.1 - 22.1年),不治疗时为37.7年(34.3 - 40.3年)。与未感染艾滋病毒的个体相比,感染艾滋病毒的个体中结核病所致死亡的比例更高,但因结核病损失的生命年数更少。结核病后的DALY在及时治疗时占总DALY的52.5%,延迟治疗时占42.7%,不治疗时占9.1%。忽略进行性肺损伤和结核病后遗症的建模方法低估了结核病的终生健康损失48 - 57%,并低估了及时治疗的益处45 - 64%。
与及时治疗相比,延迟开始结核病治疗在疾病发作期间及之后会导致更大的肺损伤和更高的死亡风险。在结核病和艾滋病毒共同流行的地区,考虑这些因素会大幅增加对结核病所致终生疾病负担和预期寿命损失的估计。这些发现表明,与先前的分析方法相比,预防结核病并尽早开始治疗的干预措施对健康的影响更大且更具成本效益。
美国国立卫生研究院。